Drug Development · us
Plaque Reduction Without Clinical Benefit: Acumen to Stop Development of Alzheimer’s Drug Sabirnetug
A Phase 2 trial involving 542 participants failed to demonstrate that the drug could slow cognitive and functional decline. Imaging improvements did not translate into clinical benefits, and Acumen will terminate development and reassess its next steps.
Does reducing amyloid plaques in the brain mean that people with Alzheimer’s disease can retain more of their memory and ability to manage daily life? Trial results announced by Acumen Pharmaceuticals on October 30 once again illustrated the gap between the two: although the investigational antibody sabirnetug reduced plaque burden, it did not demonstrate the expected clinical benefits in the Phase 2 ALTITUDE-AD trial. The company therefore plans to stop developing the drug.
The trial enrolled 542 people with early Alzheimer’s disease, including those with mild cognitive impairment or mild dementia due to the disease. According to the company’s announcement and reporting by *Psychiatric Times*, the randomized, double-blind, placebo-controlled study was conducted in the United States, Canada, the European Union, and the United Kingdom. Infusions were administered every four weeks, comparing doses of 35 and 50 mg/kg with placebo.
The trial’s primary test was whether treatment could slow cognitive and daily functional decline after 18 months. Neither dose met the primary efficacy endpoint on the Integrated Alzheimer’s Disease Rating Scale (iADRS); key secondary endpoints, including the Clinical Dementia Rating–Sum of Boxes (CDR-SB), also failed to show statistically significant differences. The company said neither treatment group showed a meaningful efficacy difference compared with placebo.
Biomarkers presented a different picture. The company reported that positron emission tomography scans showed significant reductions in amyloid plaques at both doses at weeks 36 and 76. Sabirnetug was designed to recognize soluble amyloid-beta oligomers rather than simply target plaques; these small protein aggregates are thought to potentially disrupt signaling between nerve cells. However, plaque reduction alone remains insufficient to demonstrate that the treatment can protect patients’ cognition and daily functioning.
The findings released so far are preliminary topline results and are insufficient to fully assess the reasons for the failure. *Psychiatric Times* noted that the announcement did not provide specific P values or effect sizes for the efficacy endpoints. On safety, the company said overall tolerability was good, but approximately 10% of participants receiving sabirnetug developed amyloid-related imaging abnormalities with edema (ARIA-E); this aggregate figure also cannot replace a full analysis of adverse events.
Acumen expects to analyze fluid biomarkers and additional imaging data over the coming weeks, but said it does not expect these data to change the efficacy conclusions. The plan to stop development also covers the open-label extension of ALTITUDE-AD. The company will take measures to conserve cash and evaluate strategic options, including its Enhanced Brain Delivery program.
### Background
Alzheimer’s research is also exploring approaches such as repairing the blood-brain barrier and improving waste clearance in the brain, with some of the evidence still coming from animal studies. The results of a single trial cannot invalidate all amyloid-related strategies, but they offer a clear reminder: whether targeting protein aggregates or the brain’s clearance systems, every approach must ultimately answer the same question—can biological changes translate into benefits that patients can perceive?